ISPOR - PAR5 ADALIMUMAB, ETANERCEPT OR INFLIXIMAB- WHAT IS THE MOST COST-EFFECTIVE ANTI-TNF-á THERAPY IN RA IN A REAL-WORLD SETTING?

Full Text

PAR5 ADALIMUMAB, ETANERCEPT OR INFLIXIMAB- WHAT IS THE MOST COST-EFFECTIVE ANTI-TNF-á THERAPY IN RA IN A REAL-WORLD SETTING?

Abstract

Authors

M Deeg M Ekelund C Runge

Back to Volume 10, Issue 6

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now